2 results
Approved WMOCompleted
Primary Objective:To assess the impact of TOOKAD® Soluble VTP on the rate of absence of definite cancer using patients onactive surveillance as a comparison (co-primary objective A).To determine the difference in risk of treatment failure associated…
Approved WMOWill not start
This study will evaluate the effectiveness and safety of a 36-week refill regimen for the PDS with ranibizumab 100 mg/mL (PDS Q36W) compared with intravitreal injections of aflibercept (2 mg) administered per a treat-and-extend regimen (aflibercept…